GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Rxsight RXST · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.47

-3.04%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Rxsight — daily RXST Delayed
Market value
$182.6m
Last close × shares
Volume
539.3k
Shares, 20 Nov 2026

About Rxsight

From its filings with the US Securities and Exchange Commission

SEC filings

Rxsight is based in Aliso Viejo, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RXST. The SEC classifies its business as ophthalmic goods. In the fiscal year to 31 December 2025, it reported revenue of $134.5m and a net loss of $38.9m. At that date it held total assets of $311.8m and shareholders' equity of $275.7m. By business, LAL brought in 80.4% of revenue, followed by L D D at 15.4% and Service Warranty, Service Contracts, And Accessories at 4.3%.

In its own words

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight® Light Adjustable Lens system (“RxSight system”) is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens®(LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (“LDD™”) and related accessories. The LAL is a premium intraocular lens (“IOL”) made from the proprietary silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (“UV”) light patterns generated by the LDD.

We designed our RxSight system to address limitations of conventional premium IOL technologies by providing doctors with a more precise and adaptable method for achieving desired visual outcomes for their patients. Conventional premium IOLs require patients to select their visual priorities before surgery and accept the optical trade-offs inherent in those choices. Surgeons must rely on a series of preoperative measurements and predictive formulae to determine the appropriate lens power. If the selected power is not optimal, the patient may experience less-than-ideal results that could require a subsequent corneal refractive procedure or other corrective measures to achieve intended vision targets.

Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗

More about Rxsight →

How it makes its money

Revenue, year to 31 Dec 2025

  • LAL $108.1m · 80.4%
  • L D D $20.7m · 15.4%
  • Service Warranty, Service Contracts, And Accessories $5.7m · 4.3%

Latest on Rxsight

Our reporting

Next results

24 Feb 2027

Due on 24 Feb 2027. Analysts expect earnings of 0.25 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Rxsight's ticker?

Rxsight trades as RXST on its US listing, under ISIN US78349D1072.

What was Rxsight's last closing price?

4.47 on 20 Nov 2026. The figure is in USD and is never converted.

When does Rxsight next report results?

Results are expected on 24 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.